綠葉製藥(02186.HK)：附屬地舒單抗注射液獲批美國臨牀試驗
格隆匯6月9日丨綠葉製藥(02186.HK)宣佈，集團附屬山東博安的產品—重組抗RANKL全人單克隆抗體注射液(地舒單抗注射液，LY 06006/ LY 01011)已獲美國食品藥品管理局(“FDA”)批准啟動臨牀試驗。
劑量為60毫克╱毫升的地舒單抗注射液(“LY 06006”)用於治療具有骨折高危風險的絕經後婦女骨質疏鬆症；增加具有骨折高危風險的男性骨質疏鬆症患者的骨量；治療骨折高危風險的糖皮質激素誘導的男性和女性骨質疏鬆症；增加因非轉移性前列腺癌接受雄激素剝奪治療所致的具有骨折高危風險的男性的骨量及增加因乳腺癌接受芳香化酶抑制劑治療所致的具有骨折高危風險的女性的骨量。
劑量為120毫克╱1.7毫升的地舒單抗注射液(“LY 01011”)用於預防多發性骨髓瘤和實體瘤骨轉移患者骨相關事件；治療不可手術切除或者手術切除可能導致嚴重功能障礙的骨鉅細胞瘤，包括成人和骨骼發育成熟的青少年患者；用於治療雙膦酸鹽難治性惡性腫瘤引發的高鈣血癥(HCM)。
LY 06006和LY 01011分別為Prolia和Xgeva的生物類似藥，在中國分別處於臨牀III期和臨牀I期。
根據公開的財務報告，Prolia(LY 06006的市場可比產品)於2019年的全球銷售額為26.7億美元，同比年增長率為16.6%，而該產品尚未於中國推出。Xgeva(LY 01011的市場可比產品)於2019年的全球銷售額為19.4億美元，同比年增長率為8.3%。Xgeva於2019年5月獲得中國上市批准。
除LY 06006/LY 01011外，集團亦有多種處於不同開發階段的生物類似藥和自有知識產權的生物創新藥品種。其中，LY 01008(貝伐珠單抗注射液，Avastin生物類似藥)的上市許可申請已獲中華人民共和國國家藥品監督管理局藥品審評中心受理。
公司表示，集團將持續加大對於生物製藥領域的研發投入，加快推進創新生物藥的佈局，進一步豐富集團產品線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
